Affiliation:
1. Department of Molecular Medicine and Medical Biotechnology University of Naples Federico II Naples Italy
2. CEINGE Biotecnologie Avanzate Franco Salvatore Naples Italy
3. DAIMedLab UOC Genetica Medica AOU Federico II Naples Italy
4. SOsD Oncoematologia Pediatrica Azienda Ospedaliero Universitaria delle Marche Ancona Italy
5. Clinica di Ematologia Azienda Ospedaliero Universitaria delle Marche Ancona Italy
6. Department of Pediatric Hematology University of Hacettepe Ankara Turkey
7. Pediatric Oncology Unit Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica Sacro Cuore Rome Italy
Abstract
AbstractCongenital Dyserythropoietic Anemia type I (CDA I) is a rare hereditary condition characterized by macrocytic/normocytic anemia, splenomegaly, iron overload, and distinct abnormalities during late erythropoiesis, particularly internuclear bridges between erythroblasts. Diagnosis of CDA I remains challenging due to its rarity, clinical heterogeneity, and overlapping phenotype with other rare hereditary anemias. In this case series, we present 36 patients with suspected CDA I. A molecular diagnosis was successfully established in 89% of cases, identifying 16 patients with CDA I through the presence of 18 causative variants in the CDAN1 or CDIN1 genes. Transcriptomic analysis of CDIN1 variants revealed impaired erythroid differentiation and disruptions in transcription, cell proliferation, and histone regulation. Conversely, 16 individuals received a different diagnosis, primarily pyruvate kinase deficiency. Comparisons between CDA I and non‐CDA I patients revealed no significant differences in erythroblast morphological features. However, hemoglobin levels and red blood cell count differed between the two groups, with non‐CDA I subjects being more severely affected. Notably, most patients with severe anemia belonged to the non‐CDA I group (82% non‐CDA I vs. 18% CDA I), with a subsequent absolute prevalence of transfusion dependency among non‐CDA I patients (100% vs. 41.7%). All patients exhibited reduced bone marrow responsiveness to anemia, with a more pronounced effect observed in non‐CDA I patients. Erythropoietin levels were significantly higher in non‐CDA I patients compared to CDA I patients. However, evaluations of erythroferrone, soluble transferrin receptor, and hepcidin revealed no significant differences in plasma concentration between the two groups.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献